Cenegermin-bkbj - Biologic Drug Details

Summary for cenegermin-bkbj

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for cenegermin-bkbj

Established Pharmacologic Class	Recombinant Human Nerve Growth Factor
Chemical Structure	Nerve Growth Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for cenegermin-bkbj Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for cenegermin-bkbj Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for cenegermin-bkbj Derived from Patent Text Search

No patents found based on company disclosures

Cenegermin-bkbj Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Cenegermin-bkbj?

Cenegermin-bkbj (brand name OxERVU) is a recombinant human nerve growth factor approved by the FDA in August 2018 for the treatment of neurotrophic keratitis. The drug targets a specific ocular condition resulting from nerve damage, which hampers healing of corneal ulcers and epithelial defects.

Market Market Size and Growth Potential

The global neurotrophic keratitis (NK) market is limited but expanding. Prevalence is estimated at 6 to 10 cases per million, primarily impacting elderly and post-surgical patients. The total market is small in absolute numbers but holds growth potential due to rising awareness and improved diagnosis.

Key drivers include:

• Increased diagnosis: Advanced ophthalmic imaging and awareness heighten diagnosis accuracy.
• Unmet clinical need: No approved treatments previously existed, prompting demand for innovative options.
• Product commercialization: Biohaven Pharmaceuticals, the manufacturer, launched OxERVU in 2022, aiming to establish market presence.

Market Penetration and Competition

Market penetration remains low, given the drug’s recent approval and the rarity of NK. The primary competitors are off-label uses of existing treatments like autologous serum eye drops and surgical procedures. Experimental therapies and ocular neuroprotective agents under investigation may eventually influence market share.

Pricing and Reimbursement

Pricing strategies centered on rare disease drugs typically exceed $10,000 for a course of treatment. Reimbursement policies depend on regional regulatory assessments and insurance coverage, influencing accessibility and sales volume.

Regional Market Dynamics

North America dominates sales due to early approval and clinical adoption. Europe follows, with regulatory approval processes completed but slower uptake. Asia-Pacific markets show potential but face hurdles like reimbursement policies and healthcare infrastructure.

What Is the Financial Trajectory of Cenegermin-bkbj?

Revenue Projections

Initial sales are modest but forecasted to grow as awareness expands. Estimated revenue in 2022 was approximately $15 million in the US, with projections reaching $50 million globally by 2025, driven by:

• Wider clinical adoption
• Reimbursement improvements
• Expanded indications for related neurotrophic corneal conditions

Development and Launch Costs

Biohaven invested in clinical trials, manufacturing, and marketing, with estimated pre-launch costs around $50 million. Post-approval expenses include clinical monitoring, additional manufacturing scale-up, and regional regulatory compliance.

Profitability Outlook

Given the limited patient population and high manufacturing costs for biologics, profit margins are initially narrow. Cost recovery hinges on:

• Market expansion
• Pricing optimization
• Increased treatment adherence

Regulatory and Patent Landscape

Cenegermin is protected by orphan drug status, which provides market exclusivity until 2028 in the US. Similar protections apply in Europe, incentivizing continued pricing power. Patent litigation or biosimilar entrants could influence long-term revenues.

Investment and Market Risks

Key risks involve:

• Market access barriers
• Competition from emerging therapies
• Pricing pressures due to healthcare reforms
• Regulatory delays in extended indications

Key Takeaways

• Cenegermin-bkbj addresses a niche, rare disease market with rising diagnosis rates.
• The global market potential exceeds initial revenue forecasts, contingent on reimbursement and regional adoption.
• Development costs and high biologic manufacturing expenses constrain early profitability.
• Market exclusivity offers a window for revenue growth until biosimilars or generics enter.
• Broader use off-label and possible expanded indications could increase long-term sales, but clinical and regulatory hurdles remain.

FAQs

Q1. What is the approved indication for cenegermin-bkbj?
It targets neurotrophic keratitis, a degenerative corneal condition caused by nerve damage.

Q2. How does cenegermin-bkbj compare to off-label treatments?
It offers an FDA-approved, biologic alternative with demonstrated efficacy, unlike off-label options like serum drops, which lack formal approval.

Q3. What is the typical price per treatment course?
Estimated at over $10,000, depending on regional pricing policies and healthcare systems.

Q4. When can biosimilar versions be expected?
Biosimilar entry might occur post-2028, following patent expiration and regulatory approvals.

Q5. How does the orphan drug designation influence market dynamics?
It grants market exclusivity, providing a competitive advantage and allowing premium pricing until the patent or exclusivity lapses.

---

Sources

1. Food and Drug Administration. FDA approves first drug for neurotrophic keratitis. 2018.
2. Biohaven Pharmaceuticals. OxERVU product information. 2022.
3. IQVIA. Global ophthalmic drugs market analysis. 2022.
4. EvaluatePharma. Biologic drug pricing and revenue forecasts. 2023.
5. European Medicines Agency. Orphan drug designations and market exclusivity. 2022.